Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HOPE S RUGO

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1033176581
CMS profile
183398
Location
SAN FRANCISCO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$67,341.61

86 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HOPE S RUGO

NPI 1033176581 · CMS profile ID 183398

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology

SAN FRANCISCO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033176581?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HOPE S RUGO, NPI 1033176581, CMS profile ID 183398. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033176581?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). HOPE S RUGO, NPI 1033176581, CMS profile ID 183398. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033176581?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
HOPE S RUGO, NPI 1033176581, CMS profile ID 183398, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1033176581?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

86 matching records · $67,341.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 86 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–86 of 86.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $2,310.0005/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186636167 CMS
Gilead Sciences, Inc. $222.1605/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234369678 CMS
PFIZER INC. $147.0405/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231348735 CMS
Gilead Sciences, Inc. $222.9605/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234369670 CMS
Gilead Sciences, Inc. $222.2505/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234369676 CMS
Gilead Sciences, Inc. $84.0305/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234371477 CMS
Gilead Sciences, Inc. $11,420.9105/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234363299 CMS
Gilead Sciences, Inc. $7,620.5105/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234363311 CMS
PFIZER INC. $3,700.0005/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1229126196 CMS
Gilead Sciences, Inc. $94.3604/30/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234371311 CMS
Daiichi Sankyo Inc. $133.2804/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197039519 CMS
Gilead Sciences, Inc. $44.4204/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234415076 CMS
Napo Pharmaceuticals Inc $3,000.0004/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1225171804 CMS
AstraZeneca Pharmaceuticals LP $86.4403/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206708759 CMS
Gilead Sciences, Inc. $56.4203/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234412602 CMS
Gilead Sciences, Inc. $112.6003/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234395930 CMS
PFIZER INC. $54.6303/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231481968 CMS
PFIZER INC. $111.9603/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231467146 CMS
AstraZeneca Pharmaceuticals LP $23.5403/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206559303 CMS
AstraZeneca Pharmaceuticals LP $114.9403/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206318843 CMS
Genentech USA, Inc. $2,320.0003/06/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1211518283 CMS
Genentech USA, Inc. $239.4903/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211518285 CMS
Stemline Therapeutics Inc. $34.0103/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244093790 CMS
Gilead Sciences, Inc. $85.3502/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234406346 CMS
Gilead Sciences, Inc. $147.9802/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234376116 CMS
Napo Pharmaceuticals Inc $181.0101/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237627888 CMS
Napo Pharmaceuticals Inc $28.8401/31/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1237627935 CMS
Napo Pharmaceuticals Inc $210.8601/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237627886 CMS
Napo Pharmaceuticals Inc $45.9601/30/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1237627933 CMS
PFIZER INC. $118.2301/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231239127 CMS
AstraZeneca Pharmaceuticals LP $120.1901/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206457887 CMS
Genentech USA, Inc. $77.9401/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211518281 CMS
AstraZeneca Pharmaceuticals LP $2,050.0001/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1207086361 CMS
E.R. Squibb & Sons, L.L.C. $2,428.2001/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1184921982 CMS
AstraZeneca Pharmaceuticals LP $31.2401/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206456426 CMS
Napo Pharmaceuticals Inc $3,000.0001/05/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1225171806 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $125,409.76 156
PY2020 $30,794.92 34
PY2021 $19,088.54 27
PY2022 $79,810.53 112
PY2023 $112,634.17 115
PY2024 $102,404.95 138
PY2025 $67,341.61 86

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $26,640.31 21
PY2025 Principal investigator $1,762,718.60 127
PY2024 Recipient $32,716.33 18
PY2024 Principal investigator $3,878,535.88 120
PY2023 Recipient $65,869.73 29
PY2023 Principal investigator $3,628,374.01 141
PY2022 Recipient $25,218.00 19
PY2022 Principal investigator $3,191,632.06 99
PY2021 Recipient $87,043.55 44
PY2021 Principal investigator $4,351,047.57 136
PY2020 Recipient $43,604.90 39
PY2020 Principal investigator $3,949,955.67 243
PY2019 Recipient $7,316.88 14
PY2019 Principal investigator $2,506,017.46 241

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

148 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $34,811.71 12/31/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan sac-TMT, MK-2870 as a Monotherapy and in Combination with PembrolizumabMK-3475 Versus Treatment of Physician's Choice in Participants With Previously Untr No dispute reported 06/30/2026 1232922938
Principal investigator 1 Merck Sharp & Dohme LLC $34,811.71 12/31/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan sac-TMT, MK-2870 as a Monotherapy and in Combination with PembrolizumabMK-3475 Versus Treatment of Physician's Choice in Participants With Previously Untr No dispute reported 06/30/2026 1232923662
Principal investigator 1 Merck Sharp & Dohme LLC $350.18 12/31/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - KEYNOTE-355 No dispute reported 06/30/2026 1232925865
Principal investigator 1 PFIZER INC. $54.70 12/18/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228709476
Principal investigator 1 PFIZER INC. $54.70 12/18/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228709636
Principal investigator 1 PFIZER INC. $54.70 12/18/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228709638
Principal investigator 1 PFIZER INC. $54.70 12/18/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228709800
Principal investigator 1 PFIZER INC. $2,177.18 12/17/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES No dispute reported 06/30/2026 1228709960
Recipient F. Hoffmann-La Roche AG $503.68 12/12/2025 Covered Recipient Physician Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211536059
Recipient F. Hoffmann-La Roche AG $292.89 12/12/2025 Covered Recipient Physician Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211536062
Principal investigator 1 PFIZER INC. $53,304.29 12/11/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228709796
Principal investigator 1 Hoffmann-La Roche Limited $4,853.64 12/10/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
Morpheus Breast Cancer No dispute reported 06/30/2026 1211547194
Recipient Novartis Pharmaceuticals Corporation $617.57 12/10/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291186
Principal investigator 1 Gilead Sciences, Inc. $117,311.00 12/09/2025 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
IMMU132-2020-050 / TBCRC 047 Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A multicenter, multi-arm Translational Breast Cancer Research Consortium study (TBCRC 047: InCITe) No dispute reported 06/30/2026 1229213608
Recipient PFIZER INC. $940.00 12/09/2025 Covered Recipient Physician LADIRATUZUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727501
Principal investigator 1 PFIZER INC. $34,174.42 11/26/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228709958
Recipient PFIZER INC. $3,200.00 11/24/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727545
Principal investigator 1 GlaxoSmithKline, LLC. $118.72 11/12/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY UCSF
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1192114767
Principal investigator 1 Hoffmann-La Roche Limited $2,426.82 11/12/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
Morpheus Breast Cancer No dispute reported 06/30/2026 1211547190
Principal investigator 1 PFIZER INC. $3,265.77 11/01/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES No dispute reported 06/30/2026 1228709956
Principal investigator 1 Astellas Pharma Global Development $1,970.22 10/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179776
Principal investigator 1 Astellas Pharma Global Development $447.55 10/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179778
Principal investigator 1 Astellas Pharma Global Development $1,860.00 10/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179780
Principal investigator 1 Astellas Pharma Global Development $665.00 10/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179782
Principal investigator 1 Astellas Pharma Global Development $2,660.00 10/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179784
Principal investigator 1 Astellas Pharma Global Development $447.55 10/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179786
Principal investigator 1 Astellas Pharma Global Development $731.50 10/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179788
Principal investigator 1 Astellas Pharma Global Development $2,460.50 10/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179790
Principal investigator 1 Astellas Pharma Global Development $9,318.11 10/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179792
Principal investigator 1 Astellas Pharma Global Development $321.36 10/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179794
Principal investigator 1 Astellas Pharma Global Development $744.79 10/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179796
Principal investigator 1 Astellas Pharma Global Development $3,115.74 10/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179798
Principal investigator 1 Astellas Pharma Global Development $2,660.00 10/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179800
Recipient F. Hoffmann-La Roche AG $1,225.57 10/18/2025 Covered Recipient Physician Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211536057
Principal investigator 1 GlaxoSmithKline, LLC. $2,660.00 10/14/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY UCSF
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1192114755
Principal investigator 1 GlaxoSmithKline, LLC. $2,460.00 10/14/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY UCSF
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1192114761
Principal investigator 1 GlaxoSmithKline, LLC. $1,600.00 10/14/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY UCSF
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1192114774
Principal investigator 1 GlaxoSmithKline, LLC. $665.00 10/14/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY UCSF
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1192114781
Principal investigator 1 GlaxoSmithKline, LLC. $305.90 10/14/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY UCSF
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1192173736
Principal investigator 1 GlaxoSmithKline, LLC. $1,330.00 10/14/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY UCSF
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1192173739
Principal investigator 1 GlaxoSmithKline, LLC. $2,460.00 10/14/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY UCSF
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1192173744
Principal investigator 1 GlaxoSmithKline, LLC. $1,330.00 10/14/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY UCSF
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1192173748
Principal investigator 1 GlaxoSmithKline, LLC. $731.50 10/14/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY UCSF
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1192173751
Principal investigator 1 GlaxoSmithKline, LLC. $4,256.00 10/14/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY UCSF
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1192173757
Principal investigator 1 GlaxoSmithKline, LLC. $2,660.00 10/14/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY UCSF
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1192173761
Principal investigator 1 GlaxoSmithKline, LLC. $339.00 10/14/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY UCSF
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1192173766
Principal investigator 1 GlaxoSmithKline, LLC. $219.45 10/14/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY UCSF
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1192174717
Principal investigator 1 Hoffmann-La Roche Limited $38,321.52 10/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
Morpheus Breast Cancer No dispute reported 06/30/2026 1211547186
Principal investigator 1 PFIZER INC. $1,088.59 10/07/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES No dispute reported 06/30/2026 1228709866
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228709478
Principal investigator 1 PFIZER INC. $54.70 10/02/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228709640
Principal investigator 1 PFIZER INC. $500.00 10/02/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228709798
Principal investigator 1 Astellas Pharma Global Development $7,980.00 09/25/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179770
Principal investigator 1 Astellas Pharma Global Development $5,320.00 09/25/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179772
Principal investigator 1 Astellas Pharma Global Development $4,921.00 09/25/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179774
Principal investigator 1 Hoffmann-La Roche Limited $2,426.82 09/17/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
Morpheus Breast Cancer No dispute reported 06/30/2026 1211547183
Principal investigator 1 PFIZER INC. $7,620.13 08/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES No dispute reported 06/30/2026 1228710892
Principal investigator 1 Daiichi Sankyo Inc. $325.20 08/25/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
DS8201-A-U303 No dispute reported 06/30/2026 1223347412
Principal investigator 1 Daiichi Sankyo Inc. $542.00 08/25/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
DS8201-A-U303 No dispute reported 06/30/2026 1223347414
Principal investigator 1 Daiichi Sankyo Inc. $542.00 08/25/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
DS8201-A-U303 No dispute reported 06/30/2026 1223347416
Principal investigator 1 Daiichi Sankyo Inc. $542.00 08/25/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
DS8201-A-U303 No dispute reported 06/30/2026 1223347418
Principal investigator 1 Hoffmann-La Roche Limited $7,823.92 08/13/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
Morpheus Breast Cancer No dispute reported 06/30/2026 1211547179
Principal investigator 1 PFIZER INC. $5,442.95 07/24/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES No dispute reported 06/30/2026 1228709484
Principal investigator 1 Hoffmann-La Roche Limited $2,426.82 07/11/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
Morpheus Breast Cancer No dispute reported 06/30/2026 1211547176
Principal investigator 1 PFIZER INC. $3,265.77 07/10/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES No dispute reported 06/30/2026 1228709486
Principal investigator 1 Janssen Research & Development, LLC $24,077.70 07/09/2025 Covered Recipient Teaching Hospital
Uc Davis Medical Center
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175176628
Principal investigator 1 Janssen Research & Development, LLC $31,977.50 07/09/2025 Covered Recipient Teaching Hospital
Uc Davis Medical Center
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175176988
Recipient PFIZER INC. $330.00 07/08/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228722860
Principal investigator 1 PFIZER INC. $103,507.60 06/26/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY No dispute reported 06/30/2026 1228709482
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228709566
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228709568
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228709570
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228709572
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228709574
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228709576
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228710800
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228710802
Principal investigator 1 Hoffmann-La Roche Limited $4,853.64 06/18/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
Morpheus Breast Cancer No dispute reported 06/30/2026 1211547172
Principal investigator 1 Genentech, Inc. $56,430.38 06/17/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211548087
Recipient PFIZER INC. $3,200.00 06/04/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228760377
Recipient PFIZER INC. $3,200.00 06/04/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228771116
Principal investigator 1 PFIZER INC. $54.70 05/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228709480
Recipient PFIZER INC. $940.00 05/30/2025 Covered Recipient Physician ELRANATAMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228752913
Principal investigator 1 Daiichi Sankyo Inc. $1,625.40 05/27/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
DS8201-A-U303 No dispute reported 06/30/2026 1223347410
Principal investigator 1 Merck Sharp & Dohme LLC $13,004.28 05/26/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - KEYNOTE-355 No dispute reported 06/30/2026 1232925863
Principal investigator 1 PFIZER INC. $1,088.59 05/22/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES No dispute reported 06/30/2026 1228709648
Principal investigator 1 Hoffmann-La Roche Limited $16,565.89 05/21/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
Morpheus Breast Cancer No dispute reported 06/30/2026 1211547163
Recipient PFIZER INC. $940.00 05/15/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228770954
Principal investigator 1 Merck Sharp & Dohme LLC $48,198.82 05/14/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metas No dispute reported 06/30/2026 1232917761
Recipient Novartis Pharmaceuticals Corporation $3,844.90 05/13/2025 Covered Recipient Physician China IITvsUS Flatiron AB No dispute reported 06/30/2026 1190292416
Recipient PFIZER INC. $330.00 05/13/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228771493
Principal investigator 1 Hoffmann-La Roche Limited $13,991.80 04/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
Morpheus Breast Cancer No dispute reported 06/30/2026 1211547167
Principal investigator 1 Genentech, Inc. $14,542.00 04/29/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC No dispute reported 06/30/2026 1211548104
Recipient PFIZER INC. $780.00 04/25/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228769062
Principal investigator 1 PFIZER INC. $2,177.18 04/23/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES No dispute reported 06/30/2026 1228709646
Recipient Novartis Pharma AG $1,445.70 04/14/2025 Covered Recipient Physician CBYL719C2301 No dispute reported 06/30/2026 1248109291
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179718
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179720
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179722
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179724
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179726
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179728
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179730
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179732
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179734
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179736
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179738
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179740
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179742
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179744
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179746
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179748
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179750
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179752
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179754
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179756
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179758
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179760
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179762
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179764
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179766
Principal investigator 1 Astellas Pharma Global Development $416.06 04/08/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234179768
Recipient PFIZER INC. $3,200.00 04/07/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228761810
Principal investigator 1 PFIZER INC. $1,088.59 04/04/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES No dispute reported 06/30/2026 1228709644
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,507.42 04/02/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF DATO-DXD VERSUS INVESTIGATORS CHOICE OF CHEMOTHERAPY IN PARTICIPANTS WITH INOPERABLE OR METASTATIC HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER WHO HAVE BEEN TREATED WITH ONE OR TWO PRIOR LINES OF SYSTEMIC CHEMOTHERAPY No dispute reported 06/30/2026 1185544153
Principal investigator 1 Hoffmann-La Roche Limited $11,021.52 03/19/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
Morpheus Breast Cancer No dispute reported 06/30/2026 1211547148
Principal investigator 1 PFIZER INC. $54.70 03/12/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228710804
Principal investigator 1 PFIZER INC. $4,354.36 02/21/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES No dispute reported 06/30/2026 1228709864
Principal investigator 1 Hoffmann-La Roche Limited $8,804.14 02/19/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
Morpheus Breast Cancer No dispute reported 06/30/2026 1211547152
Principal investigator 1 Hoffmann-La Roche Limited $12,335.76 02/19/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
Morpheus Breast Cancer No dispute reported 06/30/2026 1211547159
Principal investigator 1 Eli Lilly and Company $587.95 02/10/2025 Covered Recipient Teaching Hospital
LANGLEY PORTER PSYCHIATRIC HOSPITAL
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187874547
Principal investigator 1 PFIZER INC. $482,279.10 02/10/2025 Non-covered Recipient Entity
Johns Hopkins University
IMMUNOTHERAPY COMBINATION STRATEGIES TO TREAT TRIPLE NEGATIVE BREAST CANCER TNBCA MULTICENTER MULTIARM TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM TBCRC STUDY No dispute reported 06/30/2026 1228752718
Recipient PFIZER INC. $330.00 02/10/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228768542
Principal investigator 1 Eli Lilly and Company $2,816.76 02/06/2025 Covered Recipient Teaching Hospital
LANGLEY PORTER PSYCHIATRIC HOSPITAL
A STUDY OF LOXO-783 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ANTICANCER THERAPIES FOR PATIENTS WITH ADVANCED BREAST CANCER AND OTHER SOLID TUMORS WITH A PIK3CA H1047R MUTATION No dispute reported 06/30/2026 1187872317
Principal investigator 1 PFIZER INC. $82.50 02/04/2025 Non-covered Recipient Entity
UCSF Medical Centerat Mission Bay
A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES No dispute reported 06/30/2026 1228769669
Principal investigator 1 Daiichi Sankyo Inc. $65,776.15 01/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
DS8201-U-106 No dispute reported 06/30/2026 1223347420
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,192.94 01/30/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190305697
Principal investigator 1 PFIZER INC. $500.00 01/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228710806
Principal investigator 1 PFIZER INC. $500.00 01/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228710808
Principal investigator 1 PFIZER INC. $500.00 01/30/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228710810
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228760773
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician MAVELERTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228770488
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician MAVELERTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228770886
Recipient PFIZER INC. $330.00 01/27/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228769275
Principal investigator 1 Hoffmann-La Roche Limited $12,134.10 01/13/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
Morpheus Breast Cancer No dispute reported 06/30/2026 1211547156
Principal investigator 1 Daiichi Sankyo Inc. $7,170.35 01/09/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
DS8201-U-106 No dispute reported 06/30/2026 1223347422
Principal investigator 1 Eli Lilly and Company $381.25 01/09/2025 Non-covered Recipient Entity
WASHINGTON HOSP. HEALTHCARE SYSTEM
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187893786
Principal investigator 1 AstraZeneca Pharmaceuticals LP $339,276.44 01/03/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. No dispute reported 06/30/2026 1185544155